PhaseBio Receives FDA Breakthrough Therapy Designation and Licenses GLP-1 Analog to ImmunoForge

, , , , , , , , , ,

PhaseBio Pharmaceuticals’ antiplatelet drug PB2452 received Breakthrough Therapy designation from the U.S. FDA.

Read more
/by